维拉帕米尔调节抗微生物药物对快速生长的真菌菌的活性
Andressa Araújo Machado do Nascimento1, Carolina Trevisolli Palomo2, Regiane Bertin de Lima Scodro2
1Graduate Program in Biosciences and Physiopathology, State University Maringá, Maringá, Brazil.
概括
韦拉帕米尔 (VP) 与克洛法齐明 (CFZ) 结合,显示出对快速生长的真菌菌 (RGM) 的协同活性. 这种组合增强了CFZ的功能.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 快速增长的真菌菌菌 (RGM) 感染正在增加,需要具有挑战性的治疗.
- 优化治疗RGM的替代疗法是一个优先事项,需要快速和成本效益的方法.
- 探索药物组合提供了一个有希望的策略,以克服治疗困难和预防耐药性.
研究的目的:
- 调查维拉帕米尔 (VP) 与克拉里思罗米辛,阿米卡辛和克洛法齐明 (CFZ) 对各种RGM物种的联合活性.
- 评估维拉帕米尔在RGM感染的组合疗法中的协同作用潜力.
- 评估维拉帕米尔对现有抗菌素对RGM的疗效和耐药性概况的影响.
主要方法:
- 检查板测试以确定维拉帕米尔和抗微生物药物之间的协同活性.
- 消耗时间的试验量化了组合药物的增强的杀菌作用.
- 与临床相关的RGM小组进行测试,包括Mycobacterium smegmatis和各种Mycobacterium abscessus亚种,Mycobacterium chelonae和Mycobacterium fortuitum.
主要成果:
- 维拉帕米尔 (VP) 和克洛法齐明 (CFZ) 的组合对所有测试的RGM菌株表现出协同活性.
- 消耗时间的测试表明,VP显著提高了CFZ的杀死效率,将其抑制活性扩展了16倍.
- 维拉帕米尔与大多数经过测试的抗微生物药物,特别是CFZ,表现出调节活性,这表明其广泛适用性.
结论:
- 维拉帕米尔在与克洛法齐明相结合时,对快速生长的真菌细菌具有显著的协同潜力.
- VP-CFZ组合为改善治疗结果和对抗RGM感染中的抗菌素耐药性提供了一个有希望的策略.
- 维拉帕米尔的调节活性可能成为开发用于RGM治疗的新型协同药物选方法的模型.
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
706
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
706
Antimicrobial Proteins
745
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
745
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
402
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
402
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
190
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
190
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
834
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
834
Surface Membrane Barriers
687
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
687


